richvintage / iStockphoto.com

7 June 2018Americas

BIO 2018: Kraft president talks biotech and sport

Private capital must finance the life sciences industry in the US otherwise the country will lose its advantage in the life sciences field, claimed Jonathan Kraft, president of The Kraft Group.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

BIO 2018: Anything is possible, says first-ever human gene therapy patient

6 June 2018 “I have a message for all of you searching for a treatment and a cure in your lifetime; I hope you can look at my story and know that anything is possible,” said Ashanti DeSilva to attendees at the 2018 BIO International Convention.

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

More on this story

BIO 2018: Anything is possible, says first-ever human gene therapy patient

6 June 2018 “I have a message for all of you searching for a treatment and a cure in your lifetime; I hope you can look at my story and know that anything is possible,” said Ashanti DeSilva to attendees at the 2018 BIO International Convention.

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

More on this story

BIO 2018: Anything is possible, says first-ever human gene therapy patient

6 June 2018 “I have a message for all of you searching for a treatment and a cure in your lifetime; I hope you can look at my story and know that anything is possible,” said Ashanti DeSilva to attendees at the 2018 BIO International Convention.

BIO 2018: Former judge weighs in on differing patent standards

6 June 2018 Why has the US Supreme Court never granted certiorari on the issue of differing standards required to prove patent invalidity at district courts and at the US Patent and Trademark Office (USPTO)?

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent